by Peter Ciszewski | Jul 25, 2020
The U.S. Food and Drug Administration (FDA) has approved Tecartus (brexucabtagene autoleucel), a chimeric antigen receptor (CAR) T cell therapy, to treat adults with mantle cell lymphoma (MCL). MCL is a rare form of non-Hodgkin’s lymphoma in which B-cells become...
by Peter Ciszewski | Jul 24, 2020
Federico Grossi, MD, Chief Medical Officer at Apellis Pharmaceuticals, discusses the pathophysiology of paroxysmal nocturnal hemoglobinuria (PNH). Dr. Grossi also describes the typical symptoms and diagnostic journal that PNH patients must endure. PNH is a...
by Peter Ciszewski | Jul 23, 2020
Ashish Sagrolikar, Chief Commercial Officer of Zogenix, discusses the recent approval of Fintepla (fenfluramine) to reduce the frequency of seizures in Dravet patients 2 years of age or older. Dravet syndrome, according to the NIH, is a severe form of epilepsy...
by Peter Ciszewski | Jul 22, 2020
Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation, provides an overview of her organization. The Lymphoma Research Foundation is a nonprofit organization dedicated to funding education and research of different types of lymphoma. The...
by Peter Ciszewski | Jul 21, 2020
Diego Cadavid, MD of Fulcrum Therapeutics summarizes the several abstracts that were presented at the American Academy of Neurology Annual Meeting (AAN 2020) focused on facioscapulohumeral muscular dystrophy (FSHD) and losmapimod. FSHD is a rare progressive disease in...
